267
Participants
Start Date
October 16, 2019
Primary Completion Date
August 31, 2024
Study Completion Date
August 31, 2024
Rituximab
Biosimilar rituximab concentrate for solution for infusion
Cladribine
Mavenclad oral cladribine tablets
Department of Neurology - Kalnes, Sykehuset Østfold HF, Sarpsborg
Department of Neurology - Lillehammer, SI Lillehammer, Lillehammer
Department of Neurology - Drammen, Vestre Viken HF, Drammen
Department of Neurology - Tønsberg, Sykehuset i Vestfold HF, Tønsberg
Department of Neurology - Skien, Sykehuset Telemark, Skien
Department of Neurology, Stavanger universitetssykehus, Stavanger
Department of Neurology - Kristiansand, Sørlandet sykehus HF, Kristiansand
Department of Neurology - Førde, Helse Førde HF, Førde
St. Olavs Hospital, Trondheim University Hospital, Trondheim
Department of Neurology - Tromsø, University Hospital of North Norway, Tromsø
Department of Neurology, Oslo University Hospital, Oslo
University of Oslo
OTHER
Sykehuset Ostfold
OTHER
Sykehuset Telemark
OTHER_GOV
Vestre Viken Hospital Trust
OTHER
Sorlandet Hospital HF
OTHER_GOV
Helse Stavanger HF
OTHER_GOV
Sykehuset Innlandet HF
OTHER
Sykehuset i Vestfold HF
OTHER
University Hospital of North Norway
OTHER
St. Olavs Hospital
OTHER
Oslo University Hospital
OTHER